CRC Research Update — July 31, 2026
Today's colorectal cancer research highlights
msi-h
A collection of 52 issues
Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status
Skip to content
The CRC Digest
◆ TRIAL DATA
Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status
Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from
CRC Research Update — July 30, 2026
Today's colorectal cancer research highlights
Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer
The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to
Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC
Research comparing dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H (microsatellite instability-high) metastatic colorectal cancer. (Clinical Colorectal Cancer)
This content is informational only and does not constitute medical
CRC Research Update — July 25, 2026
Today's colorectal cancer research highlights
Severe immune-related side effects studied in 1,175 MSI-H digestive cancer patients on immunotherapy
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Severe immune-related side effects studied in 1,175 MSI-H digestive cancer patients on immunotherapy
An international study of 1,175 patients from 34 centers examined how grade 3 or higher immune-related adverse events correlate with progression-free survival and overall survival in
RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC
A meta-analysis found that oncogenic driver mutations like RAS and BRAF may contribute to clinically meaningful differences in how MSI-H/dMMR metastatic colorectal cancer responds to immune checkpoint inhibitors,
CT-Based Imaging Biomarker May Predict MSI Status
Skip to content
The CRC Digest
CT-Based Imaging Biomarker May Predict MSI Status
A retrospective study of 121 CRC patients investigated whether CT-derived extracellular volume fraction can predict microsatellite instability status non-invasively. (American Journal of Translational Research)
This content is informational only and does not constitute medical advice.
Always consult
Gut Microbiota Differs Between MSI-H and MSS Colorectal Cancer
Skip to content
The CRC Digest
Gut Microbiota Differs Between MSI-H and MSS Colorectal Cancer
A study collected fecal samples from CRC patients with different microsatellite states and healthy individuals to explore differences in gut microbiota between MSI-H and MSS colorectal cancer, potentially providing new directions for immunotherapy in MSS